Matthew I. Milowsky

18.5k citations
280 papers · 10.8k · 8 hit papers · h-index 53

Impact in

  • Surgery top 0.2%
    • Bladder and Urothelial Cancer Treatments
    • Urinary and Genital Oncology Studies
    • Prostate Cancer Treatment and Research
    • Renal cell carcinoma treatment

Papers in

    • Bladder and Urothelial Cancer Treatments 175
    • Urinary and Genital Oncology Studies 62
    • Renal cell carcinoma treatment 37
    • Prostate Cancer Treatment and Research 28

Matthew I. Milowsky

264 papers receiving 10.6k citations

Matthew I. Milowsky's Hit Papers

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline 2022 · 193 citations
1930+4+9Years since publication200400600

Peers

Matthew I. Milowsky
Comparison fields: 5 of 131
  • Surgery 5.2k
  • Pulmonary and Respiratory Medicine 3.0k
  • Oncology 2.4k
  • Urology 507
  • Cancer Research 934
Replace Matthew D. Galsky with:
Matthew D. Galsky United States
Jonathan E. Rosenberg United States
Claus Rödel Germany
George N. Thalmann Switzerland
Mitchell C. Benson United States
Manfred P. Wirth Germany
Jürgen E. Gschwend Germany
Richard Zigeuner Austria
Axel S. Merseburger Germany
Thomas Powles United Kingdom
Matthew I. Milowsky relative to Matthew D. Galsky United States Matthew D. Galsky's profile →
Citations per field
00.5×1.5×
Matthew D. Galsky · 1×
Citations per year

Countries citing papers authored by Matthew I. Milowsky

Since Specialization
Citations

This map shows the geographic impact of Matthew I. Milowsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew I. Milowsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew I. Milowsky more than expected).

Fields of papers citing papers by Matthew I. Milowsky

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew I. Milowsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew I. Milowsky. The network helps show where Matthew I. Milowsky may publish in the future.

Co-authors

The 25 scholars most cited alongside Matthew I. Milowsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthew I. Milowsky Line = papers co-authored together Matthew I. Milowsky links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 280 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Hit paper breakdown →
2014640
2
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Hit paper breakdown →
2012504
3 2005429
4
Phase II Study of Lutetium-177–Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
Hit paper breakdown →
2013331
5
A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity
Hit paper breakdown →
2017311
6 2004255
7
EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
Hit paper breakdown →
2020235
8 2018219
9
The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma
Hit paper breakdown →
2021217
10 2003207
11 2018206
12 2008202
13
Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline
Hit paper breakdown →
2022193
14 2007188
15 2016188
16 2008184
17 2016181
18 2007181
19
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer
Hit paper breakdown →
2022173
20 2012173

About Matthew I. Milowsky

Matthew I. Milowsky is a scholar working on Surgery, Pulmonary and Respiratory Medicine, Oncology, Molecular Biology and Epidemiology, having authored 280 papers that have together received 10.8k indexed citations. Recurring topics across this work include Bladder and Urothelial Cancer Treatments (175 papers), Urinary and Genital Oncology Studies (62 papers), Cancer Immunotherapy and Biomarkers (41 papers), Renal cell carcinoma treatment (37 papers), Prostate Cancer Treatment and Research (28 papers), Multiple and Secondary Primary Cancers (20 papers), Cancer Genomics and Diagnostics (12 papers) and Cancer Research and Treatments (10 papers). The work is most often cited by research in Surgery (5.2k citations), Pulmonary and Respiratory Medicine (3.0k citations), Oncology (2.4k citations), Urology (507 citations) and Cancer Research (934 citations). Matthew I. Milowsky has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include David M. Nanus, Neil H. Bander, Stanley J. Goldsmith, Dean F. Bajorin, Shankar Vallabhajosula, Lale Kostakoğlu, William Y. Kim, Gopa Iyer, Sara E. Wobker and Tracy L. Rose. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Annals of Oncology, The Journal of Urology and Clinical Genitourinary Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact